In the final part of our ACR 2020 highlights series, Peter C Taylor (University of Oxford, Oxford, UK) reviews the results from an observational multicentric study investigating the efficacy and safety of a second jakinib in patients who failed to respond, or had side effects, from a previous jakinib.
The abstract entitled ‘Efficacy and Safety of Switching Jakinibs in Rheumatoid Arthritis’ was presented at ACR Convergence 2020.
Other highlights in this series include PART 1, PART 2 and PART 3.
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
